Gout Pipeline Insight 2025: Emerging Therapies, Clinical Trials, and Treatment Updates

Strategic Insights -

DelveInsight's "Gout Pipeline Insight 2025" report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in the Gout pipeline landscape. The Gout Pipeline report covers the Gout Pipeline drug profiles, including clinical and nonclinical stage products, and highlights the inactive pipeline products in this space.

The Gout Pipeline report provides disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Gout Pipeline report also highlights the unmet needs with respect to the Gout. Gout, historically referred to as the "disease of kings and king of diseases," is one of the most common causes of chronic inflammatory arthritis, particularly in the United States. It is defined by the deposition of monosodium urate crystals in joints and surrounding tissues, driven by hyperuricemia-serum urate levels exceeding 6.8 mg/dL, the solubility threshold of urate in blood.

Key Takeaways:

  • On 01 October 2025, Amgen conducted a clinical trial to assess efficacy, safety, blood levels, and bodily effects of up to 2 dose levels of intravenous (IV) pegloticase (KRYSTEXXA) infusions at every 4-week intervals (Q4 Weeks) for up to 6 months (Day 1 to 24 weeks with an optional 24 - 48 weeks treatment duration) when given in combination with weekly oral doses of methotrexate (MTX). The goal is to identify an appropriate dose to be administered every 4 weeks to be used for future clinical trials for patients with chronic gout that does not adequately respond to conventional therapy.
  • DelveInsight's Gout Pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for Gout treatment.
  • Promising Gout Therapies such as Allopurinol, Dotinurad, Methotrexate, Pegloticase, ABP-671, D-0120, Lesinurad, DYV700, and others.
  • The report highlights the unmet needs with respect to the Gout, including the need for effective therapies to manage chronic inflammatory arthritis, reduce serum urate levels, and prevent tissue urate deposits.

Statistics:

  • 25+ companies and 30+ pipeline drugs in the Gout pipeline landscape.
  • 93% and 77% of participants receiving ABP-671 treatment experienced reduction in sUA level to less than 6 and 5 mg/dL, respectively.
  • 25+ active players working to develop 30+ pipeline therapies for Gout treatment.
  • 3,000+ patients with chronic gout that does not adequately respond to conventional therapy.

Sources:

  • M2 PressWIRE-October 20, 2025-: Gout Pipeline Drugs Report 2025: MOA, Emerging Therapies, Clinical Trials, Treatment | DelveInsight (C)1994-2025 M2 COMMUNICATIONS RDATE:17102025
  • www.abnewswire.com ((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.m2.co.uk on the world wide web. Inquiries to info@m2.co.uk))